Comprehensive Study Notes on Proto-oncogenes and Oncogenic Mutations

Overview of Proto-Oncogenes

• Proto-oncogenes represent one of the two primary groups of genes and proteins associated with cancer development, the other being tumor suppressor genes.

• Proto-oncogenes are described as the "accelerators" of cell growth.

• They are normal proteins that perform the vital function of driving cell division.

• These genes are absolutely necessary for development, specifically for transforming a fertilized egg into a complete body with differentiated tissues and functional organ systems.

• The specific types of proteins categorized as proto-oncogenes include:

  • Growth factors.

  • Growth factor receptors.

  • Kinases.

  • $GTPase$ proteins.

  • Transcription factors.

Signal Transduction Pathways and Cell Growth

• Signal transduction is the process by which a cell receives an external signal (such as a command to grow) and translates it into an internal signal to proliferate or differentiate.

• Most proteins involved in these pathways are proto-oncogenes, which are required for normal cell division.

• Growth Factors: These are the extracellular signaling molecules that the cell detects as a command to divide.

• Growth Factor Receptors: Located on the outside of the cellular membrane, these receptors detect the growth factors and interpret the signal for the interior of the cell. Often, these are tyrosine kinases.

  • Upon binding with a growth factor, the intracellular portion of the receptor protein undergoes a transformation into an activated state.

  • Once activated, the receptor phosphorylates downstream targets.

• Intracellular Signaling:

  • Cytoplasmic kinases: These reside in the cytoplasm and, once activated, phosphorylate further downstream targets.

  • Signal Amplification: The pathway is designed to amplify the initial signal by phosphorylating a large number of downstream molecules.

  • $GTPase$ Activity: Intracellular messenger molecules like $KRAS$ transduce signals by cycling between active and inactive states.

• Transcription Factors: These proteins may sit in the cytoplasm until they receive a signal, at which point they move into the nucleus. They bind to target genes in the $DNA$ to change gene expression, switching off genes that stop cell division and switching on genes that promote proliferation.

Transition from Proto-Oncogene to Oncogene

• Cells must respond to external signals to grow and develop body patterns, but they must also stop responding once the signal is removed.

• The fundamental problem in the transition to cancer is that mutated proteins lose the ability to stop responding, acting as if a growth signal is perpetually present.

• Oncogenes: These are the mutated, cancer-causing forms of proto-oncogenes.

• Activating Mutations: These are gain-of-function mutations that make the protein constitutively active (permanently "on").

• Characteristics of Genetic Alterations:

  • They are usually very specific mutations because the goal is to retain function while losing regulation.

  • They exhibit a dominant effect, meaning only one copy of the gene needs to be mutated to result in uncontrolled growth.

Point Mutations: The Case of KRAS

• $KRAS$ is a member of the $GTPase$ group of proteins, acting as an intracellular signal transducer between membrane receptors and the nucleus.

• It plays a role in proliferation, differentiation, and senescence (when cells stop dividing and are no longer actively mitotic).

• The Inactive State: By default, $KRAS$ is inactive and bound to $GDP$ ($guanosine\,diphosphate$).

• The Activation Cycle:

  • When an external signal is transduced through the receptors, $KRAS$ switches out $GDP$ for $GTP$ ($guanosine\,triphosphate$).

  • In the $GTP$-bound state, $KRAS$ is active and signals for cell growth.

• Intrinsic Regulation: The active state is unstable. $KRAS$ has an intrinsic $GTPase$ domain that automatically knocks off one phosphate group, converting $GTP$ back to $GDP$ to return to the inactive state.

• Light Switch Metaphor: Normal $KRAS$ is like a light switch that must be held down to stay on; as soon as you let go (the signal is removed), it flicks back to the off position.

• Mutant KRAS: In cancer, mutations destroy the intrinsic $GTPase$ activity. Once the mutant protein binds $GTP$, it cannot remove the phosphate. This results in the protein being "stuck" in the active state, signaling for growth even when the external signal is gone. This is likened to putting masking tape over the light switch to hold it down.

Gene Amplification: The Case of N-MYC

• $N\text{-}MYC$ is a transcription factor that controls the expression of target genes involved in the expansion of neuronal progenitors.

• It is critical during embryonic development, particularly for the formation of the brain and neural pathways.

• Normal Expression: It should be expressed at the right time and at the right level, and then switched off.

• Pathology in Neuroblastoma: These are childhood tumors arising from nerve tissue due to developmental misregulation.

• Amplification Mechanism: In tumor cells, the $N\text{-}MYC$ gene is amplified. Instead of the standard single copy per chromosome, there may be between $25$ and $700$ copies of the gene.

• Biological Impact: When the cell receives a growth signal, it produces up to $700$ times more protein than intended. This causes a massive over-response, leading to the rapid formation of large numbers of neuronal cells, appearing as lumps or neural outgrowths.

Chromosomal Translocation: BCR-ABL and the Philadelphia Chromosome

• This involves a translocation between chromosome $9$ and chromosome $22$, occurring in somatic tissues (acquired after birth).

• The Fusion Event: The break occurs in the middle of the $ABL$ gene (on chromosome $9$) and the $BCR$ gene (on chromosome $22$).

• Philadelphia Chromosome: The resulting abnormal chromosome contains the $BCR\text{-}ABL$ fusion gene.

• The Fusion Protein: The protein combines the kinase/activating domains of both genes but lacks their respective regulatory/inhibitory domains (their "brakes").

• Disease Association: This is the hallmark of Chronic Myeloid Leukaemia ($CML$). It was the first chromosomal abnormality linked to an acquired disease.

• Transforming Function: The protein acts as a constitutively active growth hormone receptor, transforming cells into a state of uncontrolled myeloid cell proliferation.

Targeted Therapy: Imatinib (Gleevec)

• The specific nature of the $BCR\text{-}ABL$ protein makes it an ideal therapeutic target.

• Drug Mechanism: Imatinib (formerly known as the patent drug Gleevec) is a tyrosine kinase inhibitor.

• Action: It binds to and blocks the kinase pocket of the $BCR\text{-}ABL$ protein. This prevents downstream substrates from binding and being phosphorylated, effectively stopping the growth signal.

• Clinical Success: Imatinib transformed $CML$ from an untreatable condition to one of the most treatable leukemias, with a five-year survival rate of approximately $90\%$.

• Refractory Patients: Some patients acquire new mutations within the kinase domain that prevent imatinib from binding while still allowing signal substrates to bind. These patients require supplementary treatments currently under clinical trial.

Summary of Proto-Oncogenes

• Normal state: Wild-type version necessary for cellular function.

• Oncogenic state: Result of activating mutations (gain-of-function).

• Genetic effect: Dominant; only one allele needs to be mutated to drive uncontrolled growth through constitutive signaling.